In 2023, the healthcare industry in China was subject to significant legislative advancements and reforms aimed at addressing industry concerns and promoting innovation. Hanshuo Zhou and Xiaoyun Wang of Jingtian & Gongcheng summarize the key events, and provide a reflective review based on their' practical experience
In 2023, significant U.S. restrictions were placed on Chinese interests. Charles Wu of Clyde & Co reviews the legislative changes, and offers practical insights into their potential impact, and the path forward in 2024
2023 was a significant year for the development of legislation and case law on intellectual property rights in China, as explored by Aggie Liu, Partner, and Hao Meng, Associate, from FenXun, which operates a joint legal platform with Baker McKenzie in China
Current sanctions, the risk of future sanctions, and foreign investment controls are some of the increasingly prominent challenges facing merger & acquisition (M&A) deals involving Chinese parties this year. While there is no universal solution for each transaction, there are still ways parties and lawyers can minimize the risk of problems arising.
Casper Sek of Jingtian & Gongcheng examines new implementation guidelines for data transfers and explains how these fit into the wider context of cooperation within the Greater Bay Area, as well as how companies will benefit
Former China COO of Morgan Stanley compares the challenges of being a senior executive at a boutique private equity firm against that of a bulge bracket investment bank
Wei Huang, Wendy Zhou and Lujia Yu, antitrust specialists at Beijing Tian Yuan Law Firm, examine the landmark Supreme People's Court judgment in re Yangtze River Pharma et al. v HIPI Pharma et al
A recent change in rules amends the jurisdiction of the IP tribunal of China's highest court, potentially freeing up judicial resources. Fang Qi and Danlei Wu of Fangda Partners review the new rules and their impact
Once the bill passes, Singapore will join such countries as China, Japan, the U.S., Australia and the U.K., which have comparable investment regulations.
Fang Qi and Danlei Wu of Fangda Partners examine the Supreme People's Court's annual summary of its landmark anti-monopoly and anti-unfair competition cases. This year's cases reveal the Court's focus on business ethics among other trends
